SCHEMBL1531387

SCHEMBL1531387

CCN(CCCN(C)C)C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA9 Q16790 2/20 0.41
LMNA P02545 2/20 0.38
ALDH1A1 P00352 3/20 0.36
HRH4 Q9H3N8 2/20 0.36
CYP1A2 P05177 1/20 0.36
HRH2 P25021 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
TSHR P16473 1/20 0.36
DNM1 Q05193 4/20 0.36
USP2 O75604 1/20 0.36
HSD17B10 Q99714 1/20 0.35
KDM5A P29375 1/20 0.34
KDM5C P41229 1/20 0.34
KDM5D Q9BY66 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
PAOX Q6QHF9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27811822 0.98 CA12 (0.39) CA12CA1CA9LMNAALDH1A1
Iodomethane SCHEMBL7516696 0.96 CA12 (0.38) CA12CA1CA9LMNAALDH1A1
SCHEMBL9129669 0.89 KDM5A (0.39) CA12CA1CA9LMNAALDH1A1
SCHEMBL35601 0.89 ALDH1A1 (0.41) LMNAALDH1A1HRH4CYP1A2HRH2
SCHEMBL18762850 0.84 ALDH1A1 (0.48) ALDH1A1HRH4CYP1A2HRH2TDP1
SCHEMBL293118 0.82 CA12 (0.59) CA12CA1CA9LMNAALDH1A1
SCHEMBL30620474 0.82 DNM1 (0.58) CA12CA1CA9ALDH1A1TSHR
SCHEMBL28916907 0.81 TDP1 (0.42) LMNAALDH1A1HRH4CYP1A2HRH2
SCHEMBL5197804 0.80 CA12 (0.52) CA12CA1CA9LMNAALDH1A1
SCHEMBL13185664 0.80 LMNA (0.47) CA12CA1CA9LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105622538-A One-pot high-yielding preparation of cetilistat INST MATERIA MEDICA CAMS 2016-06-01 CN claimed
EP-2480526-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PGI2 RECEPTOR AGONISTS Arena Pharmaceuticals, Inc. (US) 2012-08-01 EP claimed
CN-102203064-A Novel benzamides, their preparation and their use as medicaments BOEHRINGER INGELHEIM INT 2011-09-28 CN claimed
WO-2011037613-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PGI2 RECEPTOR AGONISTS ARENA PHARMACEUTICALS, INC. (US) 2011-03-31 WO claimed
CN-1868543-A Biodegradable high molecular gel medicine composition, its prepn. method and use thereof UNIV SICHUAN (CN) 2006-11-29 CN claimed
US-20060029662-A1 Immunomodulatory compositions and methods of use thereof GENZYME CORPORATION (US) 2006-02-09 US claimed
EP-1171136-A2 IMMUNOMODULATING COMPOSITION FOR USE ESPECIALLY IN THE TREATMENT OF INFLAMMATIONS, INFECTIONS AND SURGICAL ADHESIONS GENZYME CORPORATION (US) 2002-01-16 EP claimed
WO-2000059490-A2 IMMUNOMODULATING COMPOSITION FOR USE ESPECIALLY IN THE TREATMENT OF INFLAMMATIONS, INFECTIONS AND SURGICAL ADHESIONS GENZYME CORPORATION (US) 2000-10-12 WO claimed
WO-2025099312-A1 PEPTIDES AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF MULTIPLE SCLEROSIS CELLERYS AG (CH) 2025-05-15 WO disclosed
EP-4553083-A1 PEPTIDES AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF MULTIPLE SCLEROSIS Cellerys AG (CH) 2025-05-14 EP disclosed
WO-2025085621-A1 MULTIVALENT APTAMER-POLYMER CONJUGATES VALITOR, INC. (US) 2025-04-24 WO disclosed
EP-4508078-A2 HUMANIZED MULTIVALENT PROTEIN CONJUGATES Valitor, Inc. (US) 2025-02-19 EP disclosed
EP-4507730-A2 PURIFIED MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATES Valitor, Inc. (US) 2025-02-19 EP disclosed
CN-119213019-A Humanized multivalent protein conjugates 瓦利托尔有限公司 2024-12-27 CN disclosed
WO-2006036984-A2 STAND-ALONE FILM AND METHODS FOR MAKING THE SAME ATRIUM MEDICAL CORPORATION (US) 2006-04-06 WO disclosed
US-20060067983-A1 Stand-alone film and methods for making the same ATRIUM MEDICAL CORPORATION (US) 2006-03-30 US disclosed
US-20040180871-A1 Anti-inflammatory compositions and methods GENZYME CORPORATION 2004-09-16 US disclosed
WO-2004063181-A1 UREA DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS GENZYME CORPORATION (US) 2004-07-29 WO disclosed
EP-1171136-A2 IMMUNOMODULATING COMPOSITION FOR USE ESPECIALLY IN THE TREATMENT OF INFLAMMATIONS, INFECTIONS AND SURGICAL ADHESIONS GENZYME CORPORATION (US) 2002-01-16 EP disclosed
WO-2000059490-A2 IMMUNOMODULATING COMPOSITION FOR USE ESPECIALLY IN THE TREATMENT OF INFLAMMATIONS, INFECTIONS AND SURGICAL ADHESIONS GENZYME CORPORATION (US) 2000-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060029662-A1 Immunomodulatory compositions and methods of use thereof CD47, MSR1, CD14 CA12 1287/4885CA1 2368/4885CA9 2870/4885
US-20040180871-A1 Anti-inflammatory compositions and methods CD4, LCP2, IL6 CA12 3804/4885CA1 2776/4885CA9 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.